Bobby Soni

Director, Touchstone Innovations

Bobby is currently Director of Healthcare Investments at Touchstone Innovations, now part of the IP Group plc.

He joined Touchstone Innovations (previously Imperial Innovations) in 2015 from Novo Seeds, the early stage investment arm of Novo AS where he worked as Investment Director. Bobby has 17 years’ experience in the Life Science industry covering drug development, business development and venture capital investment. He is a Non-Executive Director of Storm Therapeutics, Enterprise Therapeutics, Artios Pharma, Pulmocide, and Autifony.

Bobby has a PhD in Biology from the University of Virginia and an undergraduate degree in Biochemistry from the University of Rochester